Yonsei Med J.  2018 Jul;59(5):567-579. 10.3349/ymj.2018.59.5.567.

Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review

• Koo KC
• Dasgupta P

• KMID: 2412647
• DOI: http://doi.org/10.3349/ymj.2018.59.5.567

Abstract

With advancements in diagnostic techniques, including molecular and clinical imaging, that directly target cancer cells, oligometastatic prostate cancer (PCa) is being diagnosed in patients who were, in the past, considered to have localized disease. With accumulating evidence, there has been a paradigm shift in considering aggressive treatments targeted at both the primary tumor and metastatic lesions in an aim to avoid and delay the need for palliative treatments and, ultimately, to achieve survival benefits. However, many questions still remain unanswered regarding the understanding of oligometastatic PCa, from its definition to optimal treatment strategies for each individual. Limited retrospective studies have suggested that interventions, including local and/or metastasis-directed therapy using surgery and radiation therapy (RT), can improve survival outcomes with minimal risk of adverse effects. Such treatments have been shown to decrease the risks of subsequent palliative interventions and to delay the start of androgen-deprivation therapy. Nevertheless, available data are insufficient to draw a reliable conclusion regarding their effect on quality of life measures and overall survival. This comprehensive review overviews data from contemporary literature that have investigated treatments, including surgery and RT, for patients with oligometastatic PCa, namely pelvic lymph node positive disease and limited distant metastases, and summarizes ongoing trials that are evaluating the feasibility of aggressive multimodal treatments.

Keyword

Neoplasm metastasis; prostatectomy; prostate cancer; radiotherapy; hormones; oligometastasis

MeSH Terms

Combined Modality Therapy
Humans
Lymph Nodes
Neoplasm Metastasis
Palliative Care
Passive Cutaneous Anaphylaxis
Prostate*
Prostatectomy
Prostatic Neoplasms*
Quality of Life
Radiotherapy
Retrospective Studies

Reference

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13:8–10. PMID: 7799047.

2. Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014; 31:735–748. PMID: 24968866.

3. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013; 123:4918–4922. PMID: 24135135.

4. James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial. JAMA Oncol. 2016; 2:348–357. PMID: 26606329.

5. Tward JD, Kokeny KE, Shrieve DC. Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol. 2013; 3:234–240. PMID: 24674370.

6. Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, et al. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014; 88:1064–1073. PMID: 24661660.

7. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015; 67:852–863. PMID: 25240974.

8. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294:238–244. PMID: 16014598.

9. Kim J, Park JS, Ham WS. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer. Investig Clin Urol. 2017; 58:307–316.

10. Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017; 14:15–25. PMID: 27725639.

11. Won AC, Gurney H, Marx G, De Souza P, Patel MI. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013; 112:E250–E255. PMID: 23879909.

12. Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015; 193:832–838. PMID: 25254935.

13. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009; 115:2388–2399. PMID: 19399748.

14. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989; 8:98–101. PMID: 2673568.

15. Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res. 2006; 66:11089–11093. PMID: 17145848.

16. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009; 27:1549–1556. PMID: 19237635.

17. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. 2014; 65:554–562. PMID: 24094576.

18. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009; 139:1315–1326. PMID: 20064377.

19. Strong VE, D'Angelica M, Tang L, Prete F, Gönen M, Coit D, et al. Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol. 2007; 14:3392–3400. PMID: 17665267.

20. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230:309–318. PMID: 10493478.

21. Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113:37–49. PMID: 9011700.

22. Furuya Y, Akakura K, Akimoto S, Inomiya H, Ito H. Pattern of progression and survival in hormonally treated metastatic prostate cancer. Int J Urol. 1999; 6:240–244. PMID: 10375186.

23. Aoun F, Peltier A, van Velthoven R. A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer. Biomed Res Int. 2014; 2014:501213. PMID: 25485280.

24. Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR. Stereotactic body radiation therapy for oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2016; 95:696–702. PMID: 27131082.

25. Clement JM, Sweeney CJ. Evolving treatment of oligometastatic hormone-sensitive prostate cancer. J Oncol Pract. 2017; 13:9–18. PMID: 28045610.

26. Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010; 57:754–761. PMID: 20106588.

27. Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015; 6:8491–8524. PMID: 25940699.

28. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2013; 2:215. PMID: 23346551.

29. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013; 11:27–32. PMID: 23010414.

30. Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014; 9:135. PMID: 24920079.

31. Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R, et al. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol. 2014; 37:227–233. PMID: 22992626.

32. Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016; 69:9–12. PMID: 26189689.

33. Ponti E, Ingrosso G, Carosi A, Di Murro L, Lancia A, Pietrasanta F, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a singlecenter experience. Clin Genitourin Cancer. 2015; 13:e279–e284. PMID: 25604915.

34. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013; 52:1622–1628. PMID: 23544357.

35. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004; 58:3–10. PMID: 14697414.

36. Tabata K, Niibe Y, Satoh T, Tsumura H, Ikeda M, Minamida S, et al. Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer. Pulm Med. 2012; 2012:541656. PMID: 22991663.

37. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018; 73:178–211. PMID: 28655541.

38. Cheng CW, Bergstralh EJ, Zincke H. Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer. 1993; 71(3 Suppl):996–1004. PMID: 7679047.

39. Frohmüller HG, Theiss M, Manseck A, Wirth MP. Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol. 1995; 27:202–206. PMID: 7601183.

40. Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002; 168:1008–1012. PMID: 12187210.

41. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol. 2014; 66:191–199. PMID: 23735200.

42. Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int. 2011; 107:1755–1761. PMID: 20942833.

43. Moschini M, Sharma V, Zattoni F, Boorjian SA, Frank I, Gettman MT, et al. Risk stratification of pN+ prostate cancer after radical prostatectomy from a large single institutional series with longterm followup. J Urol. 2016; 195:1773–1778. PMID: 26723866.

44. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7:472–479. PMID: 16750497.

45. Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol. 2009; 55:14–22. PMID: 18823693.

46. Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol. 2016; 69:788–794. PMID: 26038098.

47. Jang WS, Kim MS, Jeong WS, Chang KD, Cho KS, Ham WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases. BJU Int. 2018; 121:225–231. PMID: 28834084.

48. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014; 65:1058–1066. PMID: 24290503.

49. Antwi S, Everson TM. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol. 2014; 38:435–441. PMID: 24802851.

50. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014; 66:602–603. PMID: 24821581.

51. Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol. 2015; 194:378–385. PMID: 25711194.

52. US National Library of Medicine. Local treatment with RP for newly-diagnosed mPCa (LoMP). accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT02138721.

53. US National Library of Medicine. Cytoreductive prostatectomy in treating patients with newly diagnosed, metastatic prostate cancer. accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT02458716.

54. Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ, et al. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol. 2015; 193:111–116. PMID: 25150640.

55. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol. 2012; 188:2190–2197. PMID: 23083862.

56. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015; 67:299–309. PMID: 24571959.

57. Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015; 194:983–988. PMID: 25963190.

58. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010; 7:44–54. PMID: 19997074.

59. Fowler JF, Toma-Dasu I, Dasu A. Is the α/β ratio for prostate tumours really low and does it vary with the level of risk at diagnosis? Anticancer Res. 2013; 33:1009–1011. PMID: 23482774.

60. Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2011; 2011:439752. PMID: 22162711.

61. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012; 84:879–880. PMID: 23078897.

62. Rades D, Veninga T, Stalpers LJ, Basic H, Rudat V, Karstens JH, et al. Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol. 2007; 25:50–56. PMID: 17194905.

63. Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009; 93:14–17. PMID: 19409636.

64. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82:889–897. PMID: 21277113.

65. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol. 2013; 31:455–460. PMID: 21481619.

66. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001; 58:233–239. PMID: 11489709.

67. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009; 373:301–308. PMID: 19091394.

68. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011; 378:2104–2111. PMID: 22056152.

69. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol. 2005; 23:800–807. PMID: 15681524.

70. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016; 34:2835–2842. PMID: 27325855.

71. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387:1163–1177. PMID: 26719232.

72. US National Library of Medicine. A phase III of ADT + docetaxel +/− local RT +/− abiraterone acetate in metastatic hormone-naïve prostate cancer. (PEACE1). accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT01957436.

73. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017; 377:352–360. PMID: 28578607.

74. Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, et al. Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. J Clin Oncol. 2017; 35:1530–1541. PMID: 28300506.

75. Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017; 84:88–101. PMID: 28800492.

76. Alongi F, Schipani S, Samanes Gajate AM, Rosso A, Cozzarini C, Fiorino C, et al. [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. Tumori. 2010; 96:613–617. PMID: 20968143.

77. Yao HH, Hong MKh, Corcoran NM, Siva S, Foroudi F. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol. 2014; 10:308–321. PMID: 25155557.

78. Cho SY, Szabo Z. Molecular imaging of urogenital diseases. Semin Nucl Med. 2014; 44:93–109. PMID: 24484747.

79. Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, et al. Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med. 2015; 56:1862–1868. PMID: 26405167.

80. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008; 63:387–395. PMID: 18325358.

81. van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016; 117:732–739. PMID: 26683282.

82. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016; 13:226–235. PMID: 26902337.

83. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68) Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016; 70:926–937. PMID: 27363387.

84. US National Library of Medicine. Non-systemic treatment for patients with low-volume metastatic prostate cancer. accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT01558427.

85. US National Library of Medicine. Percutaneous high-dose radiotherapy in patients with oligometastases of prostate carcinoma (Oli-P). accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT02264379.

86. US National Library of Medicine. Best systemic therapy or best systemic therapy (BST) plus definitive treatment (radiation or surgery). accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT01751438.

87. US National Library of Medicine. Impact of radical prostatectomy as primary treatment in patients with prostate cancer with limited bone metastases (g-RAMPP). accessed on 2018 March 25. Available at: https://clinicaltrials.gov/ct2/show/NCT02454543.

88. Sooriakumaran P. Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial. BJU Int. 2017; 120:E8–E20. PMID: 28581205.

89. US National Library of Medicine. Immune responses in prostate, lung, melanoma and breast cancer patients following stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT) or brachytherapy (SBRT). accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT01777802.

90. US National Library of Medicine. Pembrolizumab and cryosurgery in treating patients with newly diagnosed, oligo-metastatic prostate cancer. accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT02489357.

91. US National Library of Medicine. Radiosurgery for patients with oligometastatic disease at initial presentation. accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT01345539.

92. US National Library of Medicine. Radiosurgery for patients recurrent oligometastatic disease. accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT01345552.

93. US National Library of Medicine. Radiotherapy for oligometastatic prostate cancer. accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT01859221.

94. US National Library of Medicine. Phase II study of SBRT as treatment for oligometastases in prostate cancer. accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT02192788.

95. US National Library of Medicine. Stereotactic radiotherapy for oligometastatic prostate cancer (CROP). accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT02563691.

96. US National Library of Medicine. Stereotactic body radiation for prostate oligometastases (ORIOLE). accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT02680587.

97. US National Library of Medicine. Intensity-modulated radiation therapy in treating patients undergoing androgen deprivation therapy for metastatic prostate cancer. accessed on 2018 January 10. Available at: https://clinicaltrials.gov/ct2/show/NCT00544830.